Amyloid-β precursor protein synthesis inhibitors for Alzheimer's disease treatment by Greig, Nigel H. et al.
Amyloid precursor protein synthesis inhibitors for Alzheimer’s 
disease treatment
Nigel H. Greig, Ph.D.1,*, Kumar Sambamurti, Ph.D.2, Debomoy K. Lahiri, Ph.D.3, and Robert 
E. Becker, M.D.1,4
1Drug Design and Development Section, Translational Gerontology Branch, Intramural Research 
Program, National Institute on Aging, National Institutes of Health, Baltimore MD, 21224, USA
2Department of Neurosciences, Medical University of South Carolina, Charleston, SC 29425, 
USA
3Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, USA
4Aristea Translational Medicine Corp., Carrabassett Valley, ME O4947, USA
New York University and Aria Neurosciences investigators have confirmed with 2-
([pyridine-2-ylmethyl]-amino)-phenol (2-PMAP) that inhibition of amyloid-β precursor 
protein (APP) synthesis offers an alternative to and possibly a significant advance over 
existing approaches to Alzheimer’s disease (AD).[1] As the repeated clinical trial failures in 
AD warn, along with all other AD investigators they now face daunting tasks ahead. 
Methods and knowledge of AD pathological mechanisms may not be available to 
successfully time 2-PMAP interventions early enough in the course of AD to prevent 
possible amyloid β–induced irreversible pathologies such as phosphorylated-tau protein. It 
may not be possible to meet US Food and Drug Administration clinical efficacy 
requirements during preclinical stages decades earlier when clinical pathology cannot be 
reversed but only prevented possibly years later.[2, 3] Methods used in AD drug 
development currently may be a barrier of equal importance to the identification of 
candidate drugs.
Methodological problems are seen in the report from Asuni et al,[1] who attempted to 
compare 2-PMAP to phenserine, another APP synthesis inhibitor. They are to be 
commended for seeking comparisons to an existing drug in the same class, rather than a less 
informative comparison to placebo. Unfortunately, their choice of methodologies invalidates 
the comparisons they offer. We bring these technicalities to readers’ attention to illustrate 
how methodological perils can mislead investigators, confuse readers, and confound AD 
drug developments.
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By using transfected Chinese hamster ovarian (CHO) clones, not using neuronal cell 
cultures with intact APP synthesis regulatory elements,[4] and risking variable drug 
bioavailability, the authors reported a misleading minimal effective concentration for 
phenserine of 5 to 25μM.[1] Unlike outcomes in neuronal cells,[4, 5] we found phenserine 
relatively inactive using CHO clones (unpublished data). Phenserine is also highly lipophilic 
(clog P n-octanol/water partition value = 2.22 (vs. 0.925 for 2-PAM) ((i.e., a 160-fold 
preference for the lipid vs. aqueous phase for phenserine vs. 8-fold for 2-PAM)). We found it 
necessary to use the tartrate salt in preclinical/clinical studies to provide reliable aqueous 
bioavailability.[4] The use by Asuni and colleagues[1] of free base phenserine risks 
functional concentrations far lower than they reported.
Readers not familiar in depth with human clinical pharmacology could easily miss that 
Asuni and colleagues’ reported micromolar phenserine concentrations are unachievable in 
human brain and therefore in conflict with published data. We expect Asuni and colleagues 
would have recognized and explained this discrepancy for readers, because they cite Lahiri 
et al,[4] in which we reported the nonchiral phenserine extracellular and intracellular median 
inhibition concentration (IC50) values for APP synthesis in neurons (0.64–1.0 and 1.14–
1.5μM, respectively) (this data derived from a concentration-dependent study to define the 
IC50 [4], albeit higher phenserine doses have been used in earlier studies). The literature 
also documents for Asuni and colleagues the relevant rapid chiral metabolism of (−)-
phenserine,[6] the cellular IC50 of 100nM for the resulting active N1,N8-bisnor-metabolite,
[5] and, of most importance, the lowering of cerebrospinal fluid APP and key AD markers in 
humans with mild cognitive impairment (i.e., clinical studies rather than cell culture ones).
[7] Each of these is inconsistent with the implications to be drawn from Asuni and 
colleagues’ reported values, which require explanation to avoid misleading readers.
The presence of these inconsistencies in Asuni and colleagues’ article should warn readers 
of the importance of methodologies. Methodologies affect study outcomes.[2] Investigators 
bear responsibility for disconfirming results using the original investigators’ methods before 
claiming and using disconfirming data in an active control comparison. Publishing 
misleading characterizations of a drug will only harden the resistance of pharmaceutical 
firms to provide their compounds to academic investigators, thus undermining the more 
informative comparisons of new drugs to existing drugs rather than to placebo. Journals are 
uniquely positioned to inform nonspecialists of how methodologies impact study outcomes.
As a major advance in AD pharmacology, 2-PMAP may have interesting theoretical 
importance as a selective APP synthesis inhibitor. Phenserine has an apparent different 
mechanistic target on mRNA regulatory elements [5] not present in transfected CHO cell 
lines and neuroprotective, neurogenic, and anti-inflammatory activities that may or may not 
prove useful in addressing the complex AD neuropathologies. Further comparisons of the 
two drugs should help clarify the utility of specific anti-APP and combined APP, 
neuroprotective, anti-inflammatory treatments in AD.
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